Drugs in R and D

SJR Rank #5,607H-index: 58SJR: 0.918Best quartile: Q2Open AccessAPC: US$3,490Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Country

Switzerland

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • PharmacologyQ2

Areas: Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Cancer Treatment and PharmacologyAntibiotics Pharmacokinetics and EfficacyPharmacogenetics and Drug MetabolismBiosimilars and Bioanalytical MethodsPharmaceutical studies and practicesDiabetes Treatment and ManagementHIV/AIDS drug development and treatmentPharmacological Effects and Toxicity StudiesPharmacology and Obesity TreatmentChronic Lymphocytic Leukemia Research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0306090120

Documents per Year

2022202509182736

Detailed Information

ISSN

1179-6901, 1174-5886

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

2.68

References per Document

34.84

Coverage

1999, 2002-2008, 2010-2025

Scope

Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy. The Journal includes: Clinical research on new and established drugs; Preclinical research of direct relevance to clinical drug development; Short communications and case study reports that meet the above criteria will also be considered; Reviews may also be considered.

Metrics from SCImago Journal Rank 2025. View on SCImago